Back

An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection

Bollman, B. A.; Nunna, N.; Bahl, K.; Hsiao, C. J.; Bennett, H.; Butler, S.; Foreman, B.; Burgomaster, K. E.; Aleshnick, M.; Kong, W.-P.; Fisher, B. E.; Ruckward, T. J.; Morabito, K. M.; Graham, B. S.; Dowd, K. A.; Pierson, T.; Carfi, A.

2022-10-11 immunology
10.1101/2022.10.11.511814 bioRxiv
Show abstract

Zika virus (ZIKV), an arbovirus transmitted by mosquitoes, was identified as a cause of congenital disease during a major outbreak in the Americas in 2016. Vaccine design strategies relied on limited available isolate sequence information due to the rapid response necessary. The first-generation ZIKV mRNA vaccine, mRNA-1325, was initially generated and, as additional strain sequences became available, a second mRNA vaccine, mRNA-1893, was developed. Herein, we compared the immune responses following mRNA-1325 and mRNA-1893 vaccination and reported that mRNA-1893 generated comparable neutralizing antibody titers to mRNA-1325 at 1/20th of the dose and provided complete protection from ZIKV challenge in non-human primates. In depth characterization of these vaccines indicated that the observed immunologic differences could be attributed to a single amino acid residue difference that compromised mRNA-1325 virus-like particle formation.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.